Neumora Therapeutics, Inc. - Common Stock (NMRA)

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion

The company said it plans to investigate a positive signal from female patients.

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated.

NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024.

NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also fell, dropping, 1.14% to 5,065.04.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P 500 also rose, gaining, 0.26% to 5,136.94.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution.

The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.

Mobile Global Esports stock is falling on Monday after the company revealed that shares of MGAM will be delisted later this week.